BioCentury | Aug 26, 2019
Company News

With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise

...etanercept-szzs in the U.S.; it already markets the biosimilar in Europe. Etanercept is a recombinant p75...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...bacteria expressing the human transmembrane domain of p75 NTR yielded a chalcone-flavonoid compound that inhibited p75...
...could include testing the compound in additional animal models of melanoma. TARGET/MARKER/PATHWAY: p75 neurotrophin receptor (p75...
...Ibáñez, National University of Singapore, Singapore email: phscfi@nus.edu.sg Elizabeth S. Eaton National University of Singapore p75 neurotrophin receptor (p75...
BioCentury | Mar 16, 2018
Clinical News

Coherus plans to resubmit BLA for Neulasta biosimilar

...has completed multiple Phase III trials. Neulasta is a pegylated G-CSF. Enbrel is a recombinant p75...
BioCentury | Mar 9, 2018
Company News

Coherus gains on plans to resubmit BLA for Neulasta biosimilar

...has completed multiple Phase III trials. Neulasta is a pegylated G-CSF. Enbrel is a recombinant p75...
BioCentury | Feb 2, 2018
Clinical News

Benepali etanercept less immunogenic than reference product in Phase III

...Japan, while Biogen has commercialization rights in the EU and Japan. Etanercept is a recombinant p75...
...Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of etanercept, a recombinant p75...
BioCentury | Jan 25, 2018
Translation in Brief

No TNFα for transplants

...Inc. (NASDAQ:AMGN), Pfizer Inc. (NYSE:PFE) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) market Enbrel, a recombinant p75...
BioCentury | Dec 15, 2017
Financial News

Clover raises RMB62.8M in series A

...NASDAQ:AMGN) markets Enbrel to treat arthritis, ankylosing spondylitis and psoriasis. The drug is a recombinant p75...
BioCentury | Dec 14, 2017
Financial News

Clover raises RMB62.8M in series A

...NASDAQ:AMGN) markets Enbrel to treat arthritis, ankylosing spondylitis and psoriasis. The drug is a recombinant p75...
BioCentury | Sep 15, 2017
Clinical News

Levicept begins Phase I of fusion protein for chronic pain

...evaluate safety and neurological assessments, as well as pharmacokinetics. LEVI-04 is a p75 neurotrophin receptor (p75...
...Business: Neurology Molecular target: p75 neurotrophin receptor (p75 NTR) ; Nerve growth factor (NGF) Description: p75...
...Status: Phase I started Milestone: NA Elizabeth S. Eaton LEVI-04 p75NTR-Fc Levicept Ltd. Pfizer Inc. Nerve growth factor (NGF) p75 neurotrophin receptor (p75...
BioCentury | Sep 14, 2017
Clinical News

Levicept begins Phase I of fusion protein for chronic pain

...with pain due to osteoarthritis (OA) of the knee. LEVI-04 is a p75 neurotrophin receptor (p75...
Items per page:
1 - 10 of 223